Abstract 198P
Background
Lenvatinib is oral tyrosine kinase inhibitor (TKI) that has been available for treatment of unresectable hepatocellular carcinoma (uHCC) in Japan since March 2018. We conducted a multicenter prospective observational study to assess overall survival (OS) of lenvatinib treatment in real world practice.
Methods
This study enrolled patients initially receiving lenvatinib for uHCC as systemic therapy who gave informed consent from July 2018 through January 2019. Observation period for each patient was up to 3 years. Kaplan-Meier method was used to estimate OS, and Cox regression analysis was used to explore factors which were associated with OS. The factors were selected with p value <0.05.
Results
A total of 713 patients were registered at 137 clinical sites, and the effectiveness analysis set were 703 patients. Patient background characteristics in 703 patients included median age:73.0 years (25 to 94), male/female: 564/139, weight: <60/≥60 kg :323/380 ,HBV/HCV/alcohol/NAFLD or NASH :137/287/167/88, modified ALBI grade 1/2a/2b/3 :216/199/258/18, BCLC stage A/B/C/D :57/291/332/11, Vp 0/1/2/3/4 :520/31/52/60/22, with/without extrahepatic metastasis :229/450, AFP level <200/≥200 ng/mL :432/240. Treatment history for uHCC was with/without transcatheter arterial chemoembolization (TACE): 513/190, median number of TACE: 3.0 times (1 to 26), with/without TKI pretreatment: 131/572. The initial dose of lenvatinib were labeled dose in 80.5% of patients <60 kg (8 mg) and 68.2% of patients ≥60 kg (12 mg), respectively. The median (range) duration of treatment with lenvatinib was 186.0 days (2-1,099 days). The median OS (95% CI) was 1.38 years (1.29-1.54 years) and the number of deaths was 445 patients. As a result of multivariate analysis, low ECOG-PS, low modified ALBI grade, low AFP level, small number of intrahepatic lesions, no bile duct involvement, no portal vein involvement and no extrahepatic involvement at baseline were associated with longer median OS.
Conclusions
This analysis showed that the effectiveness of lenvatinib in real world practice were consistent with previous reports.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eisai Co., Ltd.
Funding
Eisai Co., Ltd.
Disclosure
N. Izumi: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, Chugai, Takeda, Lily. K. Motoyoshi: Financial Interests, Personal, Full or part-time Employment: eisai. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sannofy, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin pharma, Servier Japan, Incy; Financial Interests, Personal, Advisory Board: Fuji film, Mudi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofy, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan. All other authors have declared no conflicts of interest.
Resources from the same session
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract